Studies from National Cancer Institute Describe New Findings in Nucleic Acids Research [Re-engineering an alphoid(tetO)-HAC-based vector to enable high-throughput analyses of gene function]
By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Current study results on Life Science Research have been published. According to news reporting originating from Bethesda, Maryland, by NewsRx correspondents, research stated, "Human artificial chromosome (HAC)-based vectors represent an alternative technology for gene delivery and expression with a potential to overcome the problems caused by the use of viral-based vectors. The recently developed alphoid(tetO)-HAC has an advantage over other HAC vectors because it can be easily eliminated from cells by inactivation of the HAC kinetochore via binding of tTS chromatin modifiers to its centromeric tetO sequences."
Our news editors obtained a quote from the research from National Cancer Institute, "This provides unique control for phenotypes induced by genes loaded into the alphoid(tetO)-HAC. However, inactivation of the HAC kinetochore requires transfection of cells by a retrovirus vector, a step that is potentially mutagenic. Here, we describe an approach to re-engineering the alphoid(tetO)-HAC that allows verification of phenotypic changes attributed to expression of genes from the HAC without a transfection step. In the new HAC vector, a tTS-EYFP cassette is inserted into a gene-loading site along with a gene of interest. Expression of the tTS generates a self-regulating fluctuating heterochromatin on the alphoid(tetO)-HAC that induces fast silencing of the genes on the HAC without significant effects on HAC segregation. This silencing of the HAC-encoded genes can be readily recovered by adding doxycycline."
According to the news editors, the research concluded: "The newly modified alphoid(tetO)-HAC-based system has multiple applications in gene function studies."
For more information on this research see: Re-engineering an alphoid(tetO)-HAC-based vector to enable high-throughput analyses of gene function. Nucleic Acids Symposium Series, 2013;41(10):e107. (Oxford University Press - www.oup.com/; Nucleic Acids Symposium Series - nass.oxfordjournals.org)
The news editors report that additional information may be obtained by contacting A.V. Kononenko, Laboratories of Molecular Pharmacology, National Cancer Institute, Bethesda, MD 20892, United States. Additional authors for this research include N.C. Lee, W.C. Earnshaw, N. Kouprina and V. Larionov (see also Life Science Research).
Keywords for this news article include: Bethesda, Maryland, Engineering, United States, Life Science Research, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC